Brought to you by 
Aegerion Pharmaceuticals nets $47.5mm through FOPO
11 Jul 2011
Executive Summary
Aegerion Pharmaceuticals Inc. (therapeutics for lipid disorders) has netted $47.5mm through the follow-on public offering of 3.25mm shares at $15.50. Current investors also sold 1mm shares. The company will use the funds to finish Phase III trials of lomitapide, as well as prepare and submit the NDA and launch the product. Proceeds will also support development of the drug candidate for patients under 18 years of age, and to repay the principal loan balance from Hercules Technology.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aegerion Pharmaceuticals nets $47.5mm through FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice